858816-12-3

Basic information

• Product Name: Benzene, 1-[(2,2-dimethoxyethyl)thio]-4-methoxy-
• CAS NO: 858816-12-3
• Molecular Formula: C11H16O3S
• Molecular Weight: 228.312
• Mol File: 858816-12-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzene, 1-[(2,2-dimethoxyethyl)thio]-4-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-[(2,2-dimethoxyethyl)thio]-4-methoxy-(858816-12-3)
• EPA Substance Registry System: Benzene, 1-[(2,2-dimethoxyethyl)thio]-4-methoxy-(858816-12-3)

Safety Data

• Hazardous Substances Data: 858816-12-3(Hazardous Substances Data)

Upstream product

• 696-63-9 4-Methoxybenzenethiol 
• 97-97-2 chloroacetaldehyde dimethyl acetal 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 141-52-6 sodium ethanolate 

Downstream Products

• 20532-30-3 5-methoxybenzothiophene 
• 105126-90-7 (4-methoxyphenylthio)acetaldehyde 

Relevant articles and documents

Antitumor agents. 284. new desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents

We previously reported that the biological acti-vity of analogues of desmosdumotin B (1) was dramatically changed depending on the B-ring system. A naphthalene B-ring analogue 3 exerted potent in vitro activity against a diverse panel of human tumor cell lines with GI50 values of 0.8-2.1 μM. In contrast, 1 analogues with a phenyl B-ring showed unique selective activity against P-glycoprotein (P-gp) overexpressing multidrug resistant cell line. We have now prepared and evaluated 1 analogues with bicyclic or tricyclic aromatic B-ring systems as in vitro inhibitors of human cancer cell line proliferation. Among all synthesized derivatives, 21 with a benzo[b]thiophenyl B-ring was highly active, with GI50 values of 0.06-0.16 μM, and this activity was not influenced by overexpression of P-gp. Furthermore, 21 inhibited tubulin assembly in vitro with an IC50 value of 2.0 μM and colchicine binding by 78% as well as cellular microtubule polymerization and spindle formation.

NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.